<!DOCTYPE html>
<html lang="en">
<head>
  <!-- Google tag (gtag.js) -->
  <script async src="https://www.googletagmanager.com/gtag/js?id=G-LSRR4KW715"></script>
  <script>
    window.dataLayer = window.dataLayer || [];
    function gtag(){dataLayer.push(arguments);}
    gtag('js', new Date());

    gtag('config', 'G-LSRR4KW715');
  </script>


  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>Case 30.6 - Thrombocytopaenia (ITP)</title>

  <!-- Favicon -->
  <link rel="icon" type="image/png" href="../assets/ShepTech logo.png">
  <link rel="apple-touch-icon" href="../assets/ShepTech logo.png">

  <!-- Primary Meta Tags -->
  <meta name="title" content="Case 30.6 - Thrombocytopaenia (ITP) | MD3 SCP Cases">
  <meta name="description" content="A 32-year-old with severe isolated thrombocytopaenia (plt 8) presenting with petechiae, purpura, and mucosal bleeding. Learn about ITP diagnosis, wet vs dry purpura, treatment indications, corticosteroids, IVIG, and splenectomy.">

  <!-- Open Graph / Facebook -->
  <meta property="fb:app_id" content="your_facebook_app_id">
  <meta property="og:type" content="article">
  <meta property="og:title" content="Case 30.6 - Thrombocytopaenia (ITP)">
  <meta property="og:site_name" content="MD3 SCP Cases">
  <meta property="og:description" content="A 32-year-old with severe isolated thrombocytopaenia (plt 8) presenting with petechiae, purpura, and mucosal bleeding. Learn about ITP diagnosis, wet vs dry purpura, treatment indications, corticosteroids, IVIG, and splenectomy.">
  <meta property="og:image" content="https://md3-scp.netlify.app/assets/ShepTech%20logo.png">
  <link rel="stylesheet" href="../css/case.css">

  <!-- Firebase SDK -->
  <script src="https://www.gstatic.com/firebasejs/9.22.0/firebase-app-compat.js"></script>
  <script src="https://www.gstatic.com/firebasejs/9.22.0/firebase-auth-compat.js"></script>
  <script src="https://www.gstatic.com/firebasejs/9.22.0/firebase-firestore-compat.js"></script>
</head>
<body>
  <div class="container">
    <div class="case-header">
      <a href="#" class="back-link" onclick="goBack(event)">← Back to Cases</a>
    </div>

    <h1>Case 30.6 – Thrombocytopaenia</h1>
    <p class="meta"><strong>Category:</strong> Medicine | <strong>Discipline:</strong> Haematology | <strong>Setting:</strong> Emergency Department</p>

    <h2>Case</h2>
    <p>Miss Rebecca Thompson, a 32-year-old primary school teacher, presents to the Emergency Department with a 1-week history of easy bruising, spontaneous bruises appearing on her arms and legs, and recurrent nosebleeds. This morning she noticed multiple small red dots on her lower legs. She also reports heavier than normal menstrual bleeding over the past 2 months.</p>

    <p>Three weeks ago, she had a viral upper respiratory tract infection which resolved with symptomatic treatment. She is otherwise fit and well with no significant past medical history. She takes no regular medications except for the combined oral contraceptive pill. She denies alcohol excess, recreational drug use, or recent travel. There is no family history of bleeding disorders.</p>

    <div class="vital-signs">
      <strong>On Examination:</strong>
      <ul>
        <li>General: Well-appearing, not in distress</li>
        <li>Temperature: 36.8°C, Heart rate: 78 bpm, BP: 118/72 mmHg, RR: 14/min, SpO₂: 99% on air</li>
        <li>Cardiovascular: Heart sounds normal, no murmurs</li>
        <li>Respiratory: Clear chest</li>
        <li>Abdomen: Soft, non-tender, <strong>no hepatosplenomegaly</strong>, no lymphadenopathy</li>
        <li>Skin: <strong>Multiple petechiae</strong> on both lower legs (non-blanching, pinpoint red-purple lesions). <strong>Extensive purpura and ecchymoses</strong> (bruises) of varying ages on both arms and legs, ranging from fresh (purple-red) to old (yellow-green).</li>
        <li>Mouth: No oral petechiae, no gum bleeding currently, no lymphadenopathy</li>
        <li>No signs of active bleeding</li>
      </ul>
    </div>

    <h2>Investigations</h2>
    <div class="investigation-results">
      <strong>Full Blood Count:</strong>
      <ul>
        <li>Hb: 128 g/L (normal 115-165 g/L for women) - Normal</li>
        <li>WCC: 7.2 × 10⁹/L (normal 4-11 × 10⁹/L) - Normal</li>
        <li>Neutrophils: 4.5 × 10⁹/L - Normal</li>
        <li><strong>Platelets: 8 × 10⁹/L</strong> (normal 150-400 × 10⁹/L) - <strong>Severe thrombocytopaenia</strong></li>
        <li>MCV: 88 fL - Normal</li>
      </ul>
      <strong>Blood Film:</strong>
      <ul>
        <li>Severe thrombocytopaenia confirmed</li>
        <li>Occasional large platelets seen</li>
        <li>Red cell and white cell morphology normal</li>
        <li><strong>No schistocytes, no abnormal cells</strong></li>
      </ul>
      <br>
      <strong>Coagulation Screen:</strong>
      <ul>
        <li>PT: 12 seconds (normal 11-13 seconds) - Normal</li>
        <li>APTT: 28 seconds (normal 25-35 seconds) - Normal</li>
        <li>Fibrinogen: 3.2 g/L (normal 2-4 g/L) - Normal</li>
      </ul>
      <strong>Biochemistry:</strong>
      <ul>
        <li>Urea: 4.8 mmol/L, Creatinine: 72 μmol/L - Normal renal function</li>
        <li>Bilirubin: 14 μmol/L, ALT: 28 U/L, ALP: 88 U/L - Normal liver function</li>
        <li>LDH: 180 U/L (normal 100-250 U/L) - Normal</li>
      </ul>
      <strong>Peripheral blood HIV and Hepatitis serology:</strong> Negative
    </div>

    <h2>Questions</h2>

    <div class="question">
      <h3>Question 1: Given the severe isolated thrombocytopaenia with otherwise normal blood counts and the clinical presentation, what is the most likely diagnosis, and what is the differential diagnosis of thrombocytopaenia?</h3>
      <button class="toggle-answer">Show Answer</button>
      <div class="answer">
        <p><strong>Most Likely Diagnosis: Immune Thrombocytopenia (ITP)</strong></p>

        <p><strong>Evidence for ITP:</strong></p>
        <ul>
          <li><strong>Severe isolated thrombocytopaenia</strong> (platelets 8 × 10⁹/L) with normal Hb and WCC</li>
          <li>Mucocutaneous bleeding (petechiae, purpura, ecchymoses, epistaxis, menorrhagia)</li>
          <li>Young, otherwise healthy woman (ITP peak incidence: adults 20-40 years, F:M = 2-3:1)</li>
          <li><strong>No hepatosplenomegaly or lymphadenopathy</strong> (excludes many secondary causes)</li>
          <li>Normal coagulation screen (PT, APTT, fibrinogen) - excludes coagulopathy</li>
          <li>Recent viral URTI (common trigger for ITP)</li>
          <li>No medications known to cause thrombocytopaenia (except OCP which is not typically associated)</li>
          <li>Normal blood film (no schistocytes - excludes TTP/HUS)</li>
        </ul>

        <p><strong>What is ITP?</strong></p>
        <p>Immune Thrombocytopenia (formerly Idiopathic Thrombocytopenic Purpura) is an <strong>acquired autoimmune disorder</strong> characterized by:</p>
        <ul>
          <li><strong>Isolated thrombocytopaenia</strong> (platelets &lt;100 × 10⁹/L, often &lt;30 × 10⁹/L)</li>
          <li><strong>Autoantibody-mediated platelet destruction</strong> (typically IgG anti-platelet antibodies targeting GPIIb/IIIa or GPIb/IX)</li>
          <li>Premature destruction in spleen (and liver)</li>
          <li>Impaired platelet production (antibodies also affect megakaryocytes)</li>
          <li><strong>Diagnosis of exclusion</strong> - no definitive diagnostic test</li>
        </ul>

        <p><strong>Classification of ITP by Duration:</strong></p>
        <ul>
          <li><strong>Newly diagnosed:</strong> &lt;3 months from diagnosis</li>
          <li><strong>Persistent:</strong> 3-12 months</li>
          <li><strong>Chronic:</strong> >12 months</li>
        </ul>

        <p><strong>Primary vs Secondary ITP:</strong></p>
        <ul>
          <li><strong>Primary ITP (80%):</strong> Isolated ITP with no identifiable underlying cause</li>
          <li><strong>Secondary ITP (20%):</strong> Associated with underlying disorders (see differential below)</li>
        </ul>

        <p><strong>Differential Diagnosis of Thrombocytopaenia:</strong></p>

        <p><strong>1. Classification by Mechanism:</strong></p>

        <table>
          <tr>
            <th>Mechanism</th>
            <th>Causes</th>
          </tr>
          <tr>
            <td><strong>Decreased Production<br>(Bone marrow failure)</strong></td>
            <td>
              <ul>
                <li>Aplastic anaemia (pancytopenia)</li>
                <li>Acute leukaemia (abnormal cells, pancytopenia)</li>
                <li>Myelodysplastic syndrome (MDS)</li>
                <li>Bone marrow infiltration (metastases, lymphoma, myelofibrosis)</li>
                <li>Megaloblastic anaemia (B12/folate deficiency - macrocytosis)</li>
                <li>Drugs: Chemotherapy, alcohol, valproate</li>
                <li>Viral: HIV, EBV, parvovirus B19</li>
              </ul>
            </td>
          </tr>
          <tr>
            <td><strong>Increased Destruction</strong></td>
            <td>
              <ul>
                <li><strong>Immune Thrombocytopenia (ITP)</strong> - primary or secondary</li>
                <li>Drug-induced (heparin → HIT, quinine, NSAIDs, antibiotics)</li>
                <li>Viral infections (HIV, HCV, EBV, CMV)</li>
                <li>Autoimmune disorders (SLE, antiphospholipid syndrome)</li>
                <li>Post-transfusion purpura</li>
                <li>Microangiopathic: TTP, HUS, DIC</li>
              </ul>
            </td>
          </tr>
          <tr>
            <td><strong>Sequestration</strong></td>
            <td>
              <ul>
                <li>Hypersplenism (cirrhosis, portal hypertension, splenomegaly from any cause)</li>
              </ul>
            </td>
          </tr>
          <tr>
            <td><strong>Dilutional</strong></td>
            <td>
              <ul>
                <li>Massive transfusion</li>
              </ul>
            </td>
          </tr>
          <tr>
            <td><strong>Artefactual<br>("Pseudothrombocytopaenia")</strong></td>
            <td>
              <ul>
                <li>EDTA-dependent platelet clumping (sample in EDTA tube)</li>
                <li><strong>Most common cause of "false" low platelets</strong></li>
                <li>Repeat sample in citrate tube or check blood film</li>
              </ul>
            </td>
          </tr>
        </table>

        <p><strong>2. Key Conditions to Consider in Differential:</strong></p>

        <table>
          <tr>
            <th>Condition</th>
            <th>Distinguishing Features</th>
          </tr>
          <tr>
            <td><strong>ITP (Primary)</strong></td>
            <td>
              <strong>Isolated thrombocytopaenia</strong>, normal Hb/WCC, no organomegaly, no abnormal cells, diagnosis of exclusion
            </td>
          </tr>
          <tr>
            <td><strong>TTP/HUS<br>(Microangiopathic)</strong></td>
            <td>
              MAHA + thrombocytopaenia + AKI ± neuro signs. <strong>Schistocytes on film</strong>, ↑ LDH, ↓ haptoglobin, ↑ bilirubin.
              TTP: neuro signs, ADAMTS13 deficiency. HUS: predominant AKI, post-diarrhoea
            </td>
          </tr>
          <tr>
            <td><strong>DIC</strong></td>
            <td>
              Thrombocytopaenia + <strong>↓ fibrinogen, ↑ PT/APTT, ↑↑ D-dimer</strong>, schistocytes.
              Context: sepsis, trauma, malignancy, obstetric emergency
            </td>
          </tr>
          <tr>
            <td><strong>HIT<br>(Heparin-Induced Thrombocytopaenia)</strong></td>
            <td>
              Thrombocytopaenia developing 5-10 days after heparin exposure. <strong>THROMBOSIS</strong> common (paradoxical).
              HIT antibody test (anti-PF4/heparin antibodies). <strong>Stop heparin immediately</strong>
            </td>
          </tr>
          <tr>
            <td><strong>Drug-Induced</strong></td>
            <td>
              Recent medication: Quinine, NSAIDs, antibiotics (co-trimoxazole, vancomycin), valproate, carbimazole
            </td>
          </tr>
          <tr>
            <td><strong>Hypersplenism</strong></td>
            <td>
              <strong>Splenomegaly present</strong>, often mild pancytopenia, underlying liver disease/portal hypertension
            </td>
          </tr>
          <tr>
            <td><strong>Aplastic Anaemia</strong></td>
            <td>
              <strong>Pancytopenia</strong> (low Hb, WCC, platelets), hypocellular bone marrow, no organomegaly
            </td>
          </tr>
          <tr>
            <td><strong>Acute Leukaemia</strong></td>
            <td>
              Pancytopenia, <strong>blast cells</strong> on film/marrow, organomegaly, systemic symptoms
            </td>
          </tr>
          <tr>
            <td><strong>Secondary ITP</strong></td>
            <td>
              Associated with:<br>
              - SLE (malar rash, arthritis, +ANA, +anti-dsDNA)<br>
              - HIV/HCV (risk factors, serology +ve)<br>
              - Lymphoproliferative (CLL, lymphoma - lymphadenopathy, splenomegaly)<br>
              - Antiphospholipid syndrome (thrombosis, recurrent miscarriages, +anticardiolipin Ab)
            </td>
          </tr>
          <tr>
            <td><strong>Pseudothrombocytopaenia</strong></td>
            <td>
              <strong>No clinical bleeding</strong>. Platelet clumping on EDTA sample. Repeat in citrate tube or manual count normal
            </td>
          </tr>
        </table>

        <p><strong>This Patient:</strong></p>
        <ul>
          <li><strong>Isolated thrombocytopaenia</strong> with normal Hb, WCC (excludes aplastic anaemia, leukaemia, marrow infiltration)</li>
          <li><strong>No schistocytes</strong>, normal LDH, normal coagulation (excludes TTP/HUS, DIC)</li>
          <li><strong>No hepatosplenomegaly</strong> (excludes hypersplenism, leukaemia, lymphoma)</li>
          <li>No heparin exposure (excludes HIT)</li>
          <li>No drugs associated with thrombocytopaenia</li>
          <li>Clinical bleeding present (excludes pseudothrombocytopaenia)</li>
          <li>HIV/HCV negative</li>
          <li><strong>Diagnosis: Primary ITP</strong> (diagnosis of exclusion after ruling out secondary causes)</li>
        </ul>

        <p><strong>Further Investigations to Consider:</strong></p>
        <ul>
          <li>Autoimmune screen (ANA, anti-dsDNA, anticardiolipin antibodies) - to exclude SLE/APS</li>
          <li>Thyroid function (ITP associated with autoimmune thyroid disease)</li>
          <li>Immunoglobulins and serum electrophoresis (if older - exclude myeloma)</li>
          <li>H. pylori testing (eradication improves platelet count in 50% with ITP in some populations)</li>
          <li><strong>Bone marrow biopsy NOT routinely required</strong> unless:
            <ul>
              <li>Atypical features (abnormal WCC/Hb, abnormal cells, hepatosplenomegaly)</li>
              <li>Age >60 years (exclude MDS)</li>
              <li>Failure to respond to first-line treatment</li>
              <li>Planning splenectomy</li>
            </ul>
          </li>
        </ul>
      </div>
    </div>

    <div class="question">
      <h3>Question 2: What are the clinical features and bleeding risk assessment in ITP, and when should treatment be initiated?</h3>
      <button class="toggle-answer">Show Answer</button>
      <div class="answer">
        <p><strong>Clinical Features of ITP:</strong></p>

        <p><strong>1. Bleeding Manifestations:</strong></p>
        <p>Bleeding severity correlates with platelet count (but individual variation exists):</p>

        <table>
          <tr>
            <th>Platelet Count</th>
            <th>Bleeding Risk</th>
            <th>Clinical Features</th>
          </tr>
          <tr>
            <td>>50 × 10⁹/L</td>
            <td>Minimal risk</td>
            <td>
              Usually asymptomatic<br>
              Normal haemostasis for most procedures
            </td>
          </tr>
          <tr>
            <td>30-50 × 10⁹/L</td>
            <td>Mild risk</td>
            <td>
              Easy bruising<br>
              Prolonged bleeding after trauma/surgery
            </td>
          </tr>
          <tr>
            <td>10-30 × 10⁹/L</td>
            <td>Moderate risk</td>
            <td>
              Spontaneous bruising<br>
              <strong>Petechiae</strong> (especially lower legs - gravity-dependent)<br>
              <strong>Purpura</strong> (larger areas of bleeding into skin)<br>
              <strong>Mucosal bleeding:</strong> Epistaxis, gum bleeding, menorrhagia<br>
              Post-traumatic bleeding
            </td>
          </tr>
          <tr>
            <td>&lt;10 × 10⁹/L</td>
            <td>High risk</td>
            <td>
              Extensive petechiae and purpura<br>
              Mucosal bleeding (epistaxis, gingival bleeding, menorrhagia)<br>
              GI bleeding, haematuria (less common)<br>
              <strong>Risk of serious bleeding</strong> (ICH, major GI bleed)
            </td>
          </tr>
        </table>

        <p><strong>Characteristic Bleeding Pattern - "Wet" vs "Dry" Purpura:</strong></p>
        <ul>
          <li><strong>"Dry" purpura:</strong> Skin bleeding only (petechiae, purpura, ecchymoses)</li>
          <li><strong>"Wet" purpura:</strong> Mucosal bleeding (oral petechiae, epistaxis, gum bleeding, menorrhagia, GI bleeding)
            <ul>
              <li><strong>"Wet" purpura indicates higher bleeding risk</strong> and more urgent need for treatment</li>
            </ul>
          </li>
        </ul>

        <p><strong>2. Life-Threatening Bleeding (Rare but Critical):</strong></p>
        <ul>
          <li><strong>Intracranial haemorrhage (ICH):</strong> 0.5-1% of ITP patients, usually when platelets &lt;10 × 10⁹/L
            <ul>
              <li>Most feared complication</li>
              <li>Presents with headache, altered consciousness, focal neurology, seizures</li>
              <li>Requires <strong>emergency platelet transfusion + IV corticosteroids + IV immunoglobulin</strong></li>
            </ul>
          </li>
          <li><strong>Major GI bleeding:</strong> Haematemesis, melaena, significant rectal bleeding</li>
          <li><strong>Retinal haemorrhage:</strong> Can cause vision loss</li>
        </ul>

        <p><strong>3. Examination Findings:</strong></p>
        <ul>
          <li><strong>Petechiae:</strong> Pinpoint (1-2mm) non-blanching red-purple lesions, often lower legs</li>
          <li><strong>Purpura:</strong> Larger (\&gt;3mm) areas of bleeding, do not blanch</li>
          <li><strong>Ecchymoses:</strong> Bruises of varying ages (purple-red → green-yellow as healing)</li>
          <li><strong>No hepatosplenomegaly or lymphadenopathy</strong> (if present, consider secondary cause)</li>
          <li>No features of systemic illness (excludes secondary causes like SLE)</li>
        </ul>

        <p><strong>Bleeding Risk Assessment:</strong></p>

        <p><strong>Factors INCREASING bleeding risk in ITP:</strong></p>
        <ul>
          <li>Platelet count &lt;10-20 × 10⁹/L</li>
          <li><strong>Mucosal bleeding ("wet" purpura)</strong></li>
          <li>Rapid fall in platelet count</li>
          <li>Co-existing platelet dysfunction (e.g., aspirin/NSAID use, uraemia)</li>
          <li>Co-existing coagulopathy (anticoagulation, liver disease)</li>
          <li>Need for invasive procedures or surgery</li>
          <li>High-risk activities (contact sports, occupational hazards)</li>
          <li>Older age (vessel fragility)</li>
          <li>Hypertension (especially uncontrolled)</li>
        </ul>

        <p><strong>Factors NOT increasing bleeding risk:</strong></p>
        <ul>
          <li>Duration of thrombocytopaenia (chronic stable low platelets often well tolerated)</li>
          <li>Mild skin bleeding alone ("dry" purpura) - less concerning if stable</li>
        </ul>

        <p><strong>When to Treat ITP - Indications for Treatment:</strong></p>

        <p><strong>ITP treatment is NOT based solely on platelet count!</strong> Treatment decisions depend on:</p>
        <ol>
          <li>Bleeding symptoms</li>
          <li>Platelet count</li>
          <li>Patient factors (age, lifestyle, comorbidities)</li>
          <li>Need for procedures</li>
        </ol>

        <p><strong>Treatment Indications:</strong></p>

        <table>
          <tr>
            <th>Scenario</th>
            <th>Treatment Approach</th>
          </tr>
          <tr>
            <td><strong>Active bleeding or "wet" purpura<br>(Any platelet count)</strong></td>
            <td>
              <strong>TREAT</strong><br>
              Indicates high risk regardless of count
            </td>
          </tr>
          <tr>
            <td><strong>Platelets &lt;20-30 × 10⁹/L<br>(Even if asymptomatic)</strong></td>
            <td>
              <strong>TREAT</strong><br>
              High risk of serious bleeding
            </td>
          </tr>
          <tr>
            <td><strong>Platelets 30-50 × 10⁹/L<br>+ High bleeding risk factors</strong><br>(Surgery, anticoagulation, high-risk occupation)</td>
            <td>
              <strong>TREAT</strong><br>
              Aim for platelet count >50 × 10⁹/L before procedures
            </td>
          </tr>
          <tr>
            <td><strong>Platelets 30-50 × 10⁹/L<br>Asymptomatic, low-risk</strong></td>
            <td>
              <strong>Consider treatment or watch and wait</strong><br>
              Individualized decision<br>
              Consider patient preference, lifestyle
            </td>
          </tr>
          <tr>
            <td><strong>Platelets >50 × 10⁹/L<br>Asymptomatic</strong></td>
            <td>
              <strong>NO TREATMENT</strong><br>
              Observation only<br>
              Monitor platelet count
            </td>
          </tr>
          <tr>
            <td><strong>Life-threatening bleeding<br>(ICH, major GI bleed)</strong></td>
            <td>
              <strong>EMERGENCY TREATMENT</strong><br>
              Multiple agents simultaneously:<br>
              - Platelet transfusion<br>
              - IV methylprednisolone (high-dose)<br>
              - IV immunoglobulin (IVIG)<br>
              - Consider emergency splenectomy
            </td>
          </tr>
        </table>

        <p><strong>Important Principles:</strong></p>
        <ul>
          <li><strong>Treatment goal is NOT to normalize platelet count</strong>, but to:
            <ul>
              <li>Prevent serious bleeding</li>
              <li>Maintain platelet count at safe level (typically >30 × 10⁹/L)</li>
              <li>Minimize treatment side effects</li>
            </ul>
          </li>
          <li><strong>Many patients with chronic ITP and stable platelets 20-50 × 10⁹/L do NOT require treatment</strong></li>
          <li>Patient education crucial: Avoid NSAIDs, contact sports, intramuscular injections</li>
        </ul>

        <p><strong>This Patient's Assessment:</strong></p>
        <ul>
          <li>Platelet count: 8 × 10⁹/L (<strong>severe thrombocytopaenia</strong>)</li>
          <li>Extensive petechiae, purpura, ecchymoses</li>
          <li>Mucosal bleeding: Recurrent epistaxis, menorrhagia</li>
          <li><strong>Both "dry" and "wet" purpura present</strong></li>
          <li><strong>HIGH BLEEDING RISK - REQUIRES TREATMENT</strong></li>
        </ul>
      </div>
    </div>

    <div class="question">
      <h3>Question 3: Outline the management approach for this patient with newly diagnosed ITP, including first-line, second-line, and emergency treatment options.</h3>
      <button class="toggle-answer">Show Answer</button>
      <div class="answer">
        <p><strong>Management of ITP:</strong></p>

        <p><strong>Initial Assessment and Supportive Measures:</strong></p>
        <ul>
          <li><strong>Admit if:</strong> Platelets &lt;10 × 10⁹/L, active bleeding, "wet" purpura, need for treatment monitoring</li>
          <li><strong>Avoid:</strong>
            <ul>
              <li>NSAIDs, aspirin (impair platelet function)</li>
              <li>Intramuscular injections (haematoma risk)</li>
              <li>Contact sports, high-risk activities</li>
              <li>Anticoagulation (unless essential - seek haematology advice)</li>
            </ul>
          </li>
          <li><strong>Manage menorrhagia:</strong> Tranexamic acid, hormonal contraception (continuous OCP to suppress menstruation)</li>
          <li><strong>Control hypertension</strong> if present (reduces ICH risk)</li>
          <li><strong>Patient education:</strong> Warning signs of serious bleeding (severe headache, visual changes, black stools, significant bleeding)</li>
        </ul>

        <p><strong>First-Line Treatment Options:</strong></p>

        <p><strong>1. Corticosteroids (First-line, most commonly used):</strong></p>
        <ul>
          <li><strong>Prednisolone 1 mg/kg/day PO (or dexamethasone 40mg PO daily for 4 days)</strong></li>
          <li><strong>Mechanism:</strong> Suppress autoantibody production, reduce splenic clearance of antibody-coated platelets</li>
          <li><strong>Response:</strong>
            <ul>
              <li>Platelet rise usually within 3-7 days</li>
              <li>70-80% achieve response (platelets >30 × 10⁹/L)</li>
              <li>Taper over 4-6 weeks once platelets >50 × 10⁹/L</li>
            </ul>
          </li>
          <li><strong>Advantages:</strong> Oral, inexpensive, widely available, rapid onset</li>
          <li><strong>Disadvantages:</strong>
            <ul>
              <li>Only 20-30% maintain remission after tapering (most relapse)</li>
              <li>Side effects: Weight gain, mood changes, insomnia, hyperglycaemia, osteoporosis, infection risk</li>
            </ul>
          </li>
          <li><strong>Dexamethasone pulse:</strong> Alternative - 40mg daily for 4 days, may have fewer side effects, similar efficacy</li>
        </ul>

        <p><strong>2. Intravenous Immunoglobulin (IVIG):</strong></p>
        <ul>
          <li><strong>Dose: 1 g/kg IV (or 0.4 g/kg/day for 5 days)</strong></li>
          <li><strong>Mechanism:</strong> Blocks Fc receptors on splenic macrophages → reduced platelet destruction. Also suppresses autoantibody production</li>
          <li><strong>Response:</strong>
            <ul>
              <li><strong>Rapid rise in platelets within 24-48 hours</strong> (faster than steroids)</li>
              <li>80% respond</li>
              <li><strong>Effect temporary (lasts 2-4 weeks)</strong> - not for long-term use</li>
            </ul>
          </li>
          <li><strong>Indications:</strong>
            <ul>
              <li>Severe bleeding or very low platelets (\&lt;10 × 10⁹/L) needing rapid rise</li>
              <li>Pre-procedure (surgery, dental work) - boost platelets quickly</li>
              <li>Pregnancy</li>
              <li>Contraindication to steroids</li>
            </ul>
          </li>
          <li><strong>Advantages:</strong> Fast-acting, safe in pregnancy</li>
          <li><strong>Disadvantages:</strong> Expensive, IV infusion required (4-6 hours), temporary effect, side effects (headache, fever, rarely thrombosis/renal impairment)</li>
        </ul>

        <p><strong>3. Anti-D Immunoglobulin:</strong></p>
        <ul>
          <li><strong>Only in Rh(D)-positive, non-splenectomized patients</strong></li>
          <li>Less commonly used than IVIG</li>
          <li>Mechanism: Induces mild haemolysis → preferential clearance of RBCs over platelets by spleen</li>
          <li>Response rate 60-80%, slower than IVIG</li>
        </ul>

        <p><strong>First-line Treatment Strategy:</strong></p>
        <ul>
          <li><strong>Platelets &lt;10 × 10⁹/L OR active bleeding:</strong>
            <ul>
              <li><strong>Prednisolone 1 mg/kg + IVIG 1 g/kg</strong> (combination for rapid and sustained response)</li>
            </ul>
          </li>
          <li><strong>Platelets 10-30 × 10⁹/L, no/minimal bleeding:</strong>
            <ul>
              <li><strong>Prednisolone 1 mg/kg alone</strong> (or dexamethasone pulse)</li>
            </ul>
          </li>
          <li><strong>Platelets >30 × 10⁹/L, asymptomatic:</strong>
            <ul>
              <li><strong>Watch and wait</strong> OR prednisolone (individualized)</li>
            </ul>
          </li>
        </ul>

        <p><strong>Second-Line Treatment (for refractory/relapsed ITP):</strong></p>

        <p><strong>Definition of refractory ITP:</strong> Failure to achieve response with first-line treatment OR relapse after initial response OR need for ongoing treatment to maintain safe platelet count</p>

        <p><strong>1. Thrombopoietin Receptor Agonists (TPO-RA) - Most common second-line:</strong></p>
        <ul>
          <li><strong>Agents:</strong>
            <ul>
              <li><strong>Romiplostim (Nplate):</strong> SC injection, weekly</li>
              <li><strong>Eltrombopag (Revolade):</strong> Oral, daily</li>
            </ul>
          </li>
          <li><strong>Mechanism:</strong> Stimulate platelet production by activating TPO receptor on megakaryocytes</li>
          <li><strong>Response:</strong> 70-80% achieve platelet response, sustained as long as continued</li>
          <li><strong>Advantages:</strong> Effective, well-tolerated, can use long-term</li>
          <li><strong>Disadvantages:</strong> Expensive, requires ongoing treatment (not curative), side effects (thrombosis risk, bone marrow fibrosis with long-term use, hepatotoxicity with eltrombopag)</li>
        </ul>

        <p><strong>2. Rituximab (Anti-CD20 monoclonal antibody):</strong></p>
        <ul>
          <li><strong>Dose: 375 mg/m² IV weekly for 4 weeks</strong> (or 1000mg on days 1 and 15)</li>
          <li><strong>Mechanism:</strong> Depletes B-cells → reduces autoantibody production</li>
          <li><strong>Response:</strong> 60% respond, 20-30% achieve long-term remission</li>
          <li><strong>Onset:</strong> Slow (4-8 weeks)</li>
          <li><strong>Advantages:</strong> Potential for long-term remission (years) even after stopping</li>
          <li><strong>Disadvantages:</strong> Infusion reactions, immunosuppression (infection risk, rare PML), expensive</li>
        </ul>

        <p><strong>3. Splenectomy:</strong></p>
        <ul>
          <li><strong>Definitive treatment</strong> - removes main site of platelet destruction and antibody production</li>
          <li><strong>Response: 60-70% achieve complete remission, 80-90% partial response</strong></li>
          <li><strong>Indications:</strong>
            <ul>
              <li>Failure of medical therapy</li>
              <li>Relapse after initial response</li>
              <li>Dependent on corticosteroids (to avoid long-term steroid toxicity)</li>
              <li>Usually delayed until 12 months from diagnosis (allow time for spontaneous remission)</li>
            </ul>
          </li>
          <li><strong>Pre-splenectomy:</strong>
            <ul>
              <li><strong>Vaccinations (≥2 weeks before surgery):</strong> Pneumococcus (PCV13 + PPV23), Meningococcus (MenACWY + MenB), Haemophilus influenzae type B, annual influenza</li>
              <li>Optimize platelet count (steroids ± IVIG ± TPO-RA)</li>
            </ul>
          </li>
          <li><strong>Post-splenectomy:</strong>
            <ul>
              <li><strong>Lifelong antibiotic prophylaxis:</strong> Penicillin V 250mg BD (or amoxicillin) OR if penicillin-allergic: erythromycin</li>
              <li>Patient education: Seek urgent medical attention for fever (risk of overwhelming post-splenectomy infection - OPSI)</li>
              <li>Medical alert bracelet</li>
            </ul>
          </li>
          <li><strong>Risks:</strong> Surgical complications, thrombosis (post-operative thrombocytosis), lifelong infection risk (OPSI from encapsulated organisms)</li>
        </ul>

        <p><strong>4. Other Second-line Options:</strong></p>
        <ul>
          <li><strong>Immunosuppressants:</strong> Azathioprine, mycophenolate mofetil, cyclophosphamide (rarely used now, replaced by TPO-RA/rituximab)</li>
          <li><strong>Fostamatinib:</strong> Oral spleen tyrosine kinase (SYK) inhibitor - newer agent for refractory ITP</li>
        </ul>

        <p><strong>Emergency Treatment (Life-Threatening Bleeding, e.g., ICH):</strong></p>
        <ul>
          <li><strong>Simultaneous multi-agent approach:</strong>
            <ol>
              <li><strong>Platelet transfusion:</strong> 1-2 adult doses immediately (even though rapidly destroyed, temporary haemostatic benefit)</li>
              <li><strong>IV methylprednisolone:</strong> 1 g IV daily for 3 days (high-dose pulse)</li>
              <li><strong>IVIG: 1 g/kg IV</strong> (rapid effect)</li>
              <li><strong>Consider emergency splenectomy</strong> if ongoing bleeding despite above</li>
              <li><strong>Tranexamic acid:</strong> If mucosal bleeding</li>
            </ol>
          </li>
          <li><strong>Neurosurgical consultation</strong> if ICH</li>
          <li><strong>Intensive care monitoring</strong></li>
        </ul>

        <p><strong>Treatment Algorithm Summary:</strong></p>
        <pre>
Newly Diagnosed ITP
        ↓
Assess bleeding risk (platelet count + clinical bleeding)
        ↓
<strong>High risk (plt &lt;20-30 or bleeding):</strong>
→ Prednisolone 1mg/kg ± IVIG
        ↓
Response? → Taper steroids over 4-6 weeks
        ↓
Relapse or steroid-dependent?
        ↓
<strong>Second-line:</strong>
→ TPO-RA (romiplostim/eltrombopag)
→ Rituximab
→ Splenectomy (if >12 months from diagnosis)
        ↓
Refractory to all?
→ Consider fostamatinib, clinical trials
        </pre>

        <p><strong>Management Plan for This Patient (Rebecca, 32F, plt 8 × 10⁹/L):</strong></p>

        <p><strong>1. Immediate Management:</strong></p>
        <ul>
          <li><strong>Admit to hospital</strong> (platelets &lt;10 × 10⁹/L, mucosal bleeding)</li>
          <li><strong>Start treatment:</strong>
            <ul>
              <li><strong>Prednisolone 1 mg/kg PO daily</strong> (e.g., 60-70mg if weight ~60-70kg)</li>
              <li><strong>IVIG 1 g/kg IV</strong> (single dose) - for rapid platelet rise given severe thrombocytopaenia</li>
            </ul>
          </li>
          <li><strong>Tranexamic acid 1g TDS PO</strong> for menorrhagia/epistaxis</li>
          <li><strong>Discuss continuous OCP</strong> to suppress menstruation (once platelets rising)</li>
          <li><strong>Avoid NSAIDs, IM injections</strong></li>
        </ul>

        <p><strong>2. Monitor Response:</strong></p>
        <ul>
          <li>Daily FBC initially (expect platelet rise within 3-7 days)</li>
          <li>Assess for steroid side effects</li>
          <li>Discharge when platelets >30 × 10⁹/L and bleeding controlled</li>
        </ul>

        <p><strong>3. Taper Steroids:</strong></p>
        <ul>
          <li>Once platelets >50 × 10⁹/L, gradually taper prednisolone over 4-6 weeks</li>
          <li>Monitor for relapse</li>
        </ul>

        <p><strong>4. Long-term Follow-up:</strong></p>
        <ul>
          <li>If relapse after steroid taper or steroid-dependent → <strong>consider second-line treatment</strong> (TPO-RA or rituximab)</li>
          <li>Haematology outpatient follow-up</li>
          <li>Patient education</li>
        </ul>
      </div>
    </div>

    <h2>Key Learning Points</h2>
    <div class="key-points">
      <ul>
        <li><strong>ITP</strong> is an autoimmune disorder causing <strong>isolated thrombocytopaenia</strong> due to antibody-mediated platelet destruction</li>
        <li><strong>Diagnosis of exclusion</strong> - requires normal Hb/WCC, no hepatosplenomegaly, no abnormal cells on film, normal coagulation</li>
        <li>Peak incidence: Adults 20-40 years, female preponderance (2-3:1). Often triggered by viral infection</li>
        <li>Clinical features: <strong>Petechiae, purpura, ecchymoses</strong>, mucosal bleeding (epistaxis, gum bleeding, menorrhagia). <strong>"Wet" purpura indicates higher risk</strong></li>
        <li><strong>Treatment NOT based solely on platelet count</strong> - consider bleeding symptoms, platelet level, patient factors</li>
        <li><strong>Treatment indications:</strong> Active bleeding/"wet" purpura, platelets &lt;20-30 × 10⁹/L, high bleeding risk factors</li>
        <li><strong>First-line treatment: Corticosteroids (prednisolone 1mg/kg) ± IVIG (1g/kg)</strong> for severe/bleeding cases</li>
        <li><strong>Second-line treatment:</strong> TPO receptor agonists (romiplostim, eltrombopag), rituximab, splenectomy (after 12 months)</li>
        <li><strong>Splenectomy:</strong> 60-70% achieve remission. Requires pre-op vaccinations (pneumococcus, meningococcus, Hib) and lifelong penicillin prophylaxis</li>
        <li><strong>Emergency treatment</strong> for life-threatening bleeding (ICH): Platelet transfusion + IV methylprednisolone + IVIG ± emergency splenectomy</li>
        <li>Avoid NSAIDs, IM injections, contact sports. Manage menorrhagia with tranexamic acid and hormonal suppression</li>
        <li><strong>Pseudothrombocytopaenia</strong> (EDTA-induced platelet clumping) is the most common cause of falsely low platelets - always check blood film</li>
      </ul>
    </div>

  </div>

  <!-- JavaScript -->  <script src="../js/firebase-config.js"></script>
  <script src="../js/dark-mode.js"></script>
  <script src="../js/auth.js"></script>
  <script src="../js/user-analytics.js"></script>
  <script src="../js/analytics-integration.js"></script>
  <script src="../js/completion-tracker.js"></script>
  <script src="../js/flag-tracker.js"></script>
  <script src="../js/case-interactions.js"></script>

  <script>
    // Toggle case completion
    function toggleCaseCompletion() {
      if (window.completionTracker) {
        const caseId = window.completionTracker.getCurrentCaseId();
        if (caseId) {
          window.completionTracker.toggleCompletion(caseId);
        }
      }
    }// Toggle case flag
    function toggleCaseFlag() {
      console.log('toggleCaseFlag() function called');
      console.log('window.flagTracker exists:', !!window.flagTracker);

      if (!window.flagTracker) {
        console.error('window.flagTracker is not defined!');
        alert('Flag tracker not initialized. Please refresh the page.');
        return;
      }

      const caseId = window.flagTracker.getCurrentCaseId();
      console.log('Current case ID:', caseId);

      if (!caseId) {
        console.error('Could not get case ID');
        alert('Could not determine case ID');
        return;
      }

      console.log('Calling window.flagTracker.toggleCaseFlag with caseId:', caseId);
      window.flagTracker.toggleCaseFlag(caseId);
    }

    // Update case flag button state on page load
    document.addEventListener('DOMContentLoaded', () => {
      if (window.flagTracker) {
        setTimeout(() => {
          const caseId = window.flagTracker.getCurrentCaseId();
          if (caseId) {
            window.flagTracker.updateCaseFlagButton(caseId);
          }
        }, 100);
      }
    });
    }
  </script>

</body>
</html>
